Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 11, 2025Annals of HematologyOpen Access

Predicting the toxicity-efficacy ratio of venetoclax in real-world patients

View Full Paper
Ask AI
Bookmark
Share

Authors

LOLoïc OsannoLBLucy BrocqueLBLaurent Bourguignon

Discussion

Loading...

Member takes

Overview

Observational study shows venetoclax improves hematological responses in acute myeloid leukemia, suggesting therapeutic drug monitoring can optimize treatment.

Key Points

  • To predict the toxicity-efficacy ratio of venetoclax in patients with acute myeloid leukemia.
  • Real-world clinical study including 48 adult patients with acute myeloid leukemia
  • Patients treated with venetoclax and azacytidine
  • Measured plasma concentrations and response rates
  • Inter-individual variability of plasma venetoclax concentrations was 68%
  • Higher venetoclax concentrations were correlated with better hematological responses
  • Median overall survival was 17.8 months with 1- and 2-year survival rates of 51% and 36.4%
  • Longer treatment durations improved outcomes without increasing toxicities

Cite This Study

Osanno et al. (2025) studied this question.

synapsesocial.com/papers/6940192a2d562116f28f6b64https://doi.org/10.1007/s00277-025-06531-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study2024
  2. 2Venetoclax concentration affects the incidence of haematological adverse events in patients with acute myeloid leukaemia2026
  3. 3Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival2026
  4. 4Population Pharmacokinetic Analyses and Exposure–Efficacy Relationships of Venetoclax in Chinese Pediatric Patients with Hematological Malignancy in a Real‐World Setting2026
  5. 5Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center study2025 · 2 citations